Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer: A case report

RATIONALE: The emergence of immune checkpoint inhibitors has brought new breakthroughs in the treatment of small cell lung cancer (SCLC). Programmed cell death-ligand 1 inhibitors combined with chemotherapy have been approved for the first-line treatment of extensive-stage small cell lung cancer (ES...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Liang, Zhang, Xin, Zhou, Lihua, Yang, Tao, Qiao, Yun, Jiang, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416004/
https://www.ncbi.nlm.nih.gov/pubmed/34477165
http://dx.doi.org/10.1097/MD.0000000000027138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416004/
https://www.ncbi.nlm.nih.gov/pubmed/34477165
http://dx.doi.org/10.1097/MD.0000000000027138

Ejemplares similares